This inventor holds 1 USPTO granted patent. Top assignees: Harvard College, Northeastern University, Scipher Medicine Corporation. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2026
Title: Xiao Gan and Network Medicine for Drug Repurposing
Introduction
Xiao Gan is an inventor associated with Boston, Massachusetts, and has worked with Northeastern University and Scipher Medicine Corporation. His patent work addresses network-based methods for identifying potential drug repurposing opportunities.
Latest Patents
Gan is associated with 1 patent, titled “Network Medicine Framework for Identifying Drug Repurposing Opportunities.” The invention describes methods and systems for predicting drugs that may be effective against diseases caused by pathogens, including novel pathogens.
The framework combines a protein-protein interaction network with a graph neural network, diffusion and proximity modules, and an aggregation module. The graph neural network predicts connections between candidate drug nodes and disease nodes in an embedded network representation. Other modules assess distances between relevant nodes, including pathogen-protein and drug-protein nodes. The aggregation module uses the candidate lists produced by these components to generate a ranked list of potential treatments.
Career Highlights
Gan’s work connects computational network analysis with drug discovery. His patent describes an approach for organizing biological interaction data and using it to prioritize existing drugs for further investigation against diseases.
Collaborations
Gan’s listed coworkers include Deisy Morselli Gysi and Albert-László Barabási. Their association reflects a collaborative research context spanning network science and biomedical applications.
Conclusion
Xiao Gan’s patent presents a network medicine framework that combines biological interaction data and computational prediction to identify and rank potential drug repurposing candidates.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile